Amphastar Pharmaceuticals, Inc. (AMPH) return on equity (ROE)

Return on equity · fiscal 2025
12.4%

Amphastar Pharmaceuticals, Inc. (AMPH) earned a return on equity of 12.4% in fiscal 2025 (the year ended December 31, 2025). That is 9.3 percentage points lower than the 21.8% of fiscal 2024. Figures as of 18 Nov 2026, 12:56 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
12.4%
Change on fiscal 2024
−9.3 pts
Highest on record
21.8%fiscal 2024
Lowest on record
-3.8%fiscal 2014
Fiscal years on record
142012–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Amphastar Pharmaceuticals, Inc. return on equity (ROE), in more detail

Across the 14 fiscal years on record (2012–2025), the highest was 21.8% in fiscal 2024 and the lowest -3.8% in fiscal 2014. The fiscal 2025 figure is higher than in 62% of the 13 earlier fiscal years on record, whose median is 4.7%.

History · 14 fiscal years

Return on equity by fiscal year

Amphastar Pharmaceuticals, Inc. return on equity (ROE), year by year

Amphastar Pharmaceuticals, Inc. (AMPH) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202512.4% 9.3 pts down
202421.8% 0.3 pts up
202321.5% 4.2 pts up
202217.3% 3.3 pts up
202113.9% 13.6 pts up
20200.3% 12.5 pts down
201912.8% 14.6 pts up
2018-1.7% 2.8 pts down
20171.1% 1.9 pts down
20163.0% 3.9 pts up
2015-0.9% 2.9 pts up
2014-3.8% 8.5 pts down
20134.7% 3.0 pts down
20127.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on AMPH

Amphastar Pharmaceuticals, Inc., figure by figure

Amphastar Pharmaceuticals, Inc. (AMPH) overview: price, valuation and scorecard

Amphastar Pharmaceuticals, Inc. return on equity (ROE): questions and answers

What is Amphastar Pharmaceuticals, Inc.'s return on equity?

Amphastar Pharmaceuticals, Inc. (AMPH) earned a return on equity of 12.4% in fiscal 2025 (the year ended December 31, 2025). That is 9.3 percentage points lower than the 21.8% of fiscal 2024.

Is Amphastar Pharmaceuticals, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 62% of the 13 earlier fiscal years on record, whose median is 4.7%.

What are the highest and lowest return on equity figures on record for Amphastar Pharmaceuticals, Inc.?

Across the 14 fiscal years on record (2012–2025), the highest was 21.8% in fiscal 2024 and the lowest -3.8% in fiscal 2014.

How is Amphastar Pharmaceuticals, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative. For Amphastar Pharmaceuticals, Inc. it is on record here for 14 fiscal years, 2012 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Amphastar Pharmaceuticals, Inc. (AMPH) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/AMPH/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.